ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0909

Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.

Marcus Hines1, Timothy Borbet2 and Sergei Koralov2, 1New York University Grossman School of Medicine, New York, NY, 2NYU Langone Medical Center, New York

Meeting: ACR Convergence 2025

Keywords: autoimmune diseases, B-Lymphocyte, cytokines, Interleukins, Micro-RNA

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: (0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: The microRNA(miR)29 family is encoded by two separate loci, the miR29ab1 and miR29b2c alleles. We have previously shown that the microRNA(miR)29 family regulates the survival and function of peripheral B cells by analyzing mice with miR29-deficient B cells (B29KO). Furthermore, these B29KO mice develop itching and skin inflammation akin to atopic dermatitis, with a 50% mortality rate. Our investigations using B29KO mice revealed a novel target transcript, Il4ra. This gene encodes the cytokine IL-4 which is an important signaling molecule for immune cell activation and differentiation. In B cells, IL-4 regulates class switch recombination to IgE and affinity maturation in germinal center reactions. We hypothesized that the miR29 family regulates the IL4 signaling cascade in B cells, conferring a susceptibility for developing atopic dermatitis.

Methods: miR-29ab1fl/fl mice (obtained from Dr. Mark Ansel’s lab) and miR-29b2c-/- mice (obtained from Dr. Jining Lu’s Lab) were bred with mb1-cre animals from Jax Labs and maintained on a C57BL/6J background. Littermates without full deletion of miR-29 family of miRNAs were used as controls. We employed flow cytometry, histology, ex vivo stimulation cultures, single-cell RNA sequencing, and statistical analysis software (GraphPad) to analyze data.

Results: We found B29KO B cells have higher expression of Il4ra by both qPCR and single-cell sequencing. Differential gene analysis and pathway enrichment show B29KO mice exhibit heightened IL4 signaling, reduced activation, and negative regulation of cytokine production relative to littermate controls. Ex vivo studies using B cells from B29KO mice revealed an increase in IgE class switching compared with wild-type B cells – a finding recapitulated in B29KO mice that have higher serum IgE titers. When treated with a neutralizing anti-IL4Ra antibody, the phenotype of B29KO mice are rescued from mortality. Interestingly, we found that skin swabs from phenotypic B29KO mice transferred the phenotype to healthy B29KO mice but not littermate controls. Donor and recipient mice were found to be colonized with Staphylococcus aureus and xylosus.

Conclusion: Our data suggest that regulation of Il4ra by miR-29 impacts B cells responsiveness to IL-4 signaling and, as a result, the susceptibility to atopic dermatitis in mice via genetic susceptibility and microbial triggers.


Disclosures: M. Hines: None; T. Borbet: None; S. Koralov: None.

To cite this abstract in AMA style:

Hines M, Borbet T, Koralov S. Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice. [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/loss-of-microrna29-expression-in-b-cells-and-skin-microbiota-synergize-to-promote-atopic-dermatitis-in-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/loss-of-microrna29-expression-in-b-cells-and-skin-microbiota-synergize-to-promote-atopic-dermatitis-in-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology